Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

Jing He; Xia Zhang; Yunbo Wei; Xiaolin Sun; Yaping Chen; Jun Deng; Yuebo Jin; Yuzhou Gan; Xin Hu; Rulin Jia; Chuanhui Xu; Zhaohua Hou; Yew Ann Leong; Lei Zhu; Jinhong Feng; Yuan An; Yuan Jia; Chun Li; Xu Liu; Hua Ye; Limin Ren; Ru Li; Haihong Yao; Yuhui Li; Shi Chen; Xuewu Zhang; Yin Su; Jianping Guo; Nan Shen; Eric F Morand; Di Yu; Zhanguo Li

doi:10.1038/nm.4148

Low-dose interleukin-2 treatment selectively modulates CD4⁺ T cell subsets in patients with systemic lupus erythematosus

Jing He
, Xia Zhang
, Yunbo Wei
, Xiaolin Sun
, Yaping Chen
, Jun Deng
, Yuebo Jin
, Yuzhou Gan
, Xin Hu
, Rulin Jia
, Chuanhui Xu
, Zhaohua Hou
, Yew Ann Leong
, Lei Zhu
, Jinhong Feng
, Yuan An
, Yuan Jia
, Chun Li
, Xu Liu
, Hua Ye

Limin Ren, Ru Li, Haihong Yao, Yuhui Li, Shi Chen, Xuewu Zhang, Yin Su, Jianping Guo, Nan Shen, Eric F Morand, Di Yu, Zhanguo Li

Research output: Contribution to journal › Article › Research › peer-review

531 Citations (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease characterized by altered balance of activity between effector and regulatory CD4⁺ T cells. The homeostasis of CD4⁺ T cell subsets is regulated by interleukin (IL)-2, and reduced production of IL-2 by T cells is observed in individuals with SLE. Here we report that treatment with low-dose recombinant human IL-2 selectively modulated the abundance of regulatory T (T_reg) cells, follicular helper T (T_FH) cells and IL-17-producing helper T (T_H17) cells, but not T_H1 or T_H2 cells, accompanied by marked reductions of disease activity in patients with SLE.

Original language	English
Pages (from-to)	991-993
Number of pages	3
Journal	Nature Medicine
Volume	22
Issue number	9
DOIs	https://doi.org/10.1038/nm.4148
Publication status	Published - Sept 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

autoimmunity
regulatory T cells
systemic lupus erythematosus

Access to Document

10.1038/nm.4148

Cite this

He, J., Zhang, X., Wei, Y., Sun, X., Chen, Y., Deng, J., Jin, Y., Gan, Y., Hu, X., Jia, R., Xu, C., Hou, Z., Leong, Y. A., Zhu, L., Feng, J., An, Y., Jia, Y., Li, C., Liu, X., ... Li, Z. (2016). Low-dose interleukin-2 treatment selectively modulates CD4⁺ T cell subsets in patients with systemic lupus erythematosus. Nature Medicine, 22(9), 991-993. https://doi.org/10.1038/nm.4148

@article{13306bba86e04b6a8f684f0aaf9fdcfc,

title = "Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus",

abstract = "Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease characterized by altered balance of activity between effector and regulatory CD4+ T cells. The homeostasis of CD4+ T cell subsets is regulated by interleukin (IL)-2, and reduced production of IL-2 by T cells is observed in individuals with SLE. Here we report that treatment with low-dose recombinant human IL-2 selectively modulated the abundance of regulatory T (Treg) cells, follicular helper T (TFH) cells and IL-17-producing helper T (TH17) cells, but not TH1 or TH2 cells, accompanied by marked reductions of disease activity in patients with SLE.",

keywords = "autoimmunity, regulatory T cells, systemic lupus erythematosus",

author = "Jing He and Xia Zhang and Yunbo Wei and Xiaolin Sun and Yaping Chen and Jun Deng and Yuebo Jin and Yuzhou Gan and Xin Hu and Rulin Jia and Chuanhui Xu and Zhaohua Hou and Leong, \{Yew Ann\} and Lei Zhu and Jinhong Feng and Yuan An and Yuan Jia and Chun Li and Xu Liu and Hua Ye and Limin Ren and Ru Li and Haihong Yao and Yuhui Li and Shi Chen and Xuewu Zhang and Yin Su and Jianping Guo and Nan Shen and Morand, \{Eric F\} and Di Yu and Zhanguo Li",

year = "2016",

month = sep,

doi = "10.1038/nm.4148",

language = "English",

volume = "22",

pages = "991--993",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "9",

}

He, J, Zhang, X, Wei, Y, Sun, X, Chen, Y, Deng, J, Jin, Y, Gan, Y, Hu, X, Jia, R, Xu, C, Hou, Z, Leong, YA, Zhu, L, Feng, J, An, Y, Jia, Y, Li, C, Liu, X, Ye, H, Ren, L, Li, R, Yao, H, Li, Y, Chen, S, Zhang, X, Su, Y, Guo, J, Shen, N, Morand, EF, Yu, D & Li, Z 2016, 'Low-dose interleukin-2 treatment selectively modulates CD4⁺ T cell subsets in patients with systemic lupus erythematosus', Nature Medicine, vol. 22, no. 9, pp. 991-993. https://doi.org/10.1038/nm.4148

TY - JOUR

T1 - Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

AU - He, Jing

AU - Zhang, Xia

AU - Wei, Yunbo

AU - Sun, Xiaolin

AU - Chen, Yaping

AU - Deng, Jun

AU - Jin, Yuebo

AU - Gan, Yuzhou

AU - Hu, Xin

AU - Jia, Rulin

AU - Xu, Chuanhui

AU - Hou, Zhaohua

AU - Leong, Yew Ann

AU - Zhu, Lei

AU - Feng, Jinhong

AU - An, Yuan

AU - Jia, Yuan

AU - Li, Chun

AU - Liu, Xu

AU - Ye, Hua

AU - Ren, Limin

AU - Li, Ru

AU - Yao, Haihong

AU - Li, Yuhui

AU - Chen, Shi

AU - Zhang, Xuewu

AU - Su, Yin

AU - Guo, Jianping

AU - Shen, Nan

AU - Morand, Eric F

AU - Yu, Di

AU - Li, Zhanguo

PY - 2016/9

Y1 - 2016/9

N2 - Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease characterized by altered balance of activity between effector and regulatory CD4+ T cells. The homeostasis of CD4+ T cell subsets is regulated by interleukin (IL)-2, and reduced production of IL-2 by T cells is observed in individuals with SLE. Here we report that treatment with low-dose recombinant human IL-2 selectively modulated the abundance of regulatory T (Treg) cells, follicular helper T (TFH) cells and IL-17-producing helper T (TH17) cells, but not TH1 or TH2 cells, accompanied by marked reductions of disease activity in patients with SLE.

AB - Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease characterized by altered balance of activity between effector and regulatory CD4+ T cells. The homeostasis of CD4+ T cell subsets is regulated by interleukin (IL)-2, and reduced production of IL-2 by T cells is observed in individuals with SLE. Here we report that treatment with low-dose recombinant human IL-2 selectively modulated the abundance of regulatory T (Treg) cells, follicular helper T (TFH) cells and IL-17-producing helper T (TH17) cells, but not TH1 or TH2 cells, accompanied by marked reductions of disease activity in patients with SLE.

KW - autoimmunity

KW - regulatory T cells

KW - systemic lupus erythematosus

UR - https://www.scopus.com/pages/publications/84981163508

U2 - 10.1038/nm.4148

DO - 10.1038/nm.4148

M3 - Article

AN - SCOPUS:84981163508

SN - 1078-8956

VL - 22

SP - 991

EP - 993

JO - Nature Medicine

JF - Nature Medicine

IS - 9

ER -

Low-dose interleukin-2 treatment selectively modulates CD4⁺ T cell subsets in patients with systemic lupus erythematosus

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Immune balance-regulating interleukins as targets for immunotherapy

Cite this

Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Projects

Immune balance-regulating interleukins as targets for immunotherapy

Cite this

Low-dose interleukin-2 treatment selectively modulates CD4⁺ T cell subsets in patients with systemic lupus erythematosus